Clinical trials
Rectal Cancer, Adenocarcinoma clinical trials
Below are recruiting rectal cancer, adenocarcinoma clinical trials, each written for real people, not researchers. We’re tracking 251 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05024097RecruitingPhase 2
New medicines with chemotherapy after short radiation for rectal cancer
This trial tests two new immune-related medicines (an anti–PD-1 drug and an adenosine blocker) added to standard chemotherapy after a short course of radiation for rectal cancer. It aims to improve cancer control while checking safety.
New York, New YorkAges 18–90 - NCT05081024Recruiting
Blood test biomarker to help preserve organs in rectal cancer
This study looks at a blood test (ctDNA, a way to detect cancer DNA in the bloodstream) to help doctors choose treatment that may spare organs for people with stage II–III rectal cancer. You may be followed to see how well the blood test can guide treatment decisions.
Portland, OregonAges 18 years+ - NCT05136326RecruitingPhase 2
Pre-surgery chemo-radiation for rectal cancer without MGMT
This trial studies whether adding two chemotherapy medicines (capecitabine and temozolomide) to standard pre-surgery chemo-radiation can work better for people with locally advanced rectal cancer that has a specific tumor marker pattern (MGMT “silenced”) and is mismatch-repair proficient (MSS). It aims to shrink the tumor before surgery and improve cancer control.
MilanAges 18 years+ - NCT05148767RecruitingPhase 4
UGT1A1-guided irinotecan for locally advanced rectal cancer
This trial studies whether adjusting irinotecan treatment based on a person’s UGT1A1 gene test can improve outcomes for locally advanced rectal cancer. It focuses on people who are about to start (or continue) chemoradiation and do not have cancer spread to distant organs.
Hangzhou, ZhejiangAges 18–75 - NCT05201430RecruitingPhase 3
FOLFOXIRI vs CapeOX before surgery for locally advanced rectal cancer
This trial compares two chemotherapy plans given before rectal cancer surgery to see which helps more people and works better for disease control. If you have locally advanced rectal cancer and have not had treatment yet, this study may be an option.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05450029RecruitingPhase 2
Adding immunotherapy to chemo-radiation for rectal cancer
This Phase 2 trial studies whether adding sintilimab (an immunotherapy drug) to standard chemo-radiation before surgery can improve outcomes for people with locally advanced rectal cancer. It’s aimed at tumors with certain immune “signature” scores and specific cancer stage features.
Guangzhou, GuangdongAges 18–75 - NCT05482516RecruitingPhase 3
Testing blood test–guided treatment for GI cancers in remission
This Phase 3 study tests whether giving treatment based on a positive blood test for “minimal cancer signals” (ctDNA) can help people with certain GI cancers stay cancer-free longer. It focuses on people who have finished curative-intent therapy and currently have no visible disease on scans, but their blood test is still positive.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05576480RecruitingPhase 2
Immunotherapy plus chemotherapy before surgery for rectal cancer without mismatch repair
This Phase 2 study tests penpulimab (an immunotherapy medicine) given with CAPEOX chemotherapy before surgery for rectal cancer that is “MSS” (not the mismatch-repair type). It aims to shrink the tumor and improve outcomes by treating before the operation.
Shanghai, None SelectedAges 18–75 - NCT05646511RecruitingPhase 3
New chemotherapy timing tests for locally advanced rectal cancer
This Phase 3 trial compares two chemotherapy combinations given with surgery for locally advanced rectal cancer. It aims to find out which approach works better and is safer for shrinking and controlling the cancer before or around the time of treatment.
ChibaAges 18 years+ - NCT05672524RecruitingPhase 2
Tucatinib plus trastuzumab for HER2-positive rectal cancer
This Phase 2 study tests whether tucatinib combined with trastuzumab can slow or shrink rectal cancer that is HER2-positive and has certain genetic tumor features. If you qualify, you may benefit from a targeted treatment approach aimed at the HER2 pathway.
Basking Ridge, New JerseyAges 18 years+ - NCT05752136RecruitingPhase 3
Pre-surgery radiation plus immunotherapy and chemo for rectal cancer
This trial tests whether a short course of radiation before surgery, combined with the immunotherapy drug envafolimab and the chemo regimen CAPEOX, works better for shrinking locally advanced rectal cancer. It is aimed at people whose tumor is not “MMR-deficient” (it is pMMR/MSS), and it asks participants to be able to return for repeated checkups and treatments.
Hangzhou, ZhejiangAges 18 years+ - NCT05772481Recruiting
PET-MRI scan test for rectal cancer after pre-surgery treatment
This study looks at whether a special scan called PET-MRI can better show how rectal cancer responds to treatment given before surgery. If it works well, it could help doctors plan the right next steps after chemoradiotherapy.
StrasbourgAges 18–75 - NCT05883800Recruiting
Total treatment with tailored radiation for advanced rectal cancer
This study tests a “total neoadjuvant” approach—chemotherapy first, then radiation—using adaptive (tailored) radiation planning for people with locally advanced rectal cancer. It may help improve tumor control while adjusting the radiation based on how your cancer and anatomy respond.
BergenAges 18 years+ - NCT05939661RecruitingPhase 2
Total treatment before surgery for early rectal cancer
This Phase 2 study tests a “total neoadjuvant” approach, meaning you receive cancer treatment before surgery, to improve safety and effectiveness for rectal cancer. It may help by shrinking the tumor and planning a more effective operation, while researchers carefully track side effects.
OsakaAges 18 years+ - NCT05943210Recruiting
Molecular testing of rectal cancer after short-course radiation
This study looks at molecular (tumor biology) features of rectal cancer in people receiving standard short-course radiation. Your tissue and/or samples may be used to better understand the cancer and how it responds to treatment.
Chicago, IllinoisAges 18–90 - NCT05984485RecruitingPhase 3
Surgery vs chemo before surgery for low-risk rectal cancer
This trial compares two approaches for low-risk locally advanced rectal cancer: going straight to surgery (TME) versus receiving chemotherapy before surgery. The goal is to see if upfront surgery works just as well, sparing patients from chemotherapy side effects.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT06050447Recruiting
Study on treatment results for colorectal cancer
This study looks at factors that affect outcomes in people with colorectal cancer who have surgery as their main treatment. It aims to help doctors understand how to improve care.
Kaliningrad, Kaliningrad OblastAges 18 years+ - NCT06051695RecruitingPhase 1/Phase 2
CAR T cell therapy for mesothelin-positive solid tumors
This trial tests a new type of immune cell therapy (CAR T-cells) designed to target cancer cells that have a protein called mesothelin but have lost a marker that lets them hide from the immune system. It's for people with advanced solid tumors who have already tried standard treatments.
Gilbert, ArizonaAges 18 years+ - NCT06162650RecruitingPhase 2
Pre-surgery chemo-radiation therapy for rectal cancer
This trial tests a combination of chemotherapy and radiation therapy before surgery for people with mid or low rectal cancer that hasn't spread. The goal is to see if this approach works better than current treatments.
TainanAges 20 years+ - NCT06209099Recruiting
Organ preservation first for low-risk rectal cancer
This trial tests a strategy to avoid surgery by using watchful waiting after initial treatment for early-stage rectal cancer. It may help patients keep their rectum and avoid a permanent colostomy.
Beijing, Haidian DistrictAges 18–85 - NCT06229041RecruitingPhase 3
Chemo and radiation with or without immunotherapy for high-risk rectal cancer
This trial tests if adding immunotherapy to standard chemotherapy and radiation before surgery helps shrink high-risk rectal cancer and prevent it from coming back. You may be a good fit if you have a specific type of advanced rectal cancer that hasn't spread to other parts of your body.
BeijingAges 18–75 - NCT06254521RecruitingPhase 2
Tislelizumab plus chemo before surgery for MSS rectal cancer
This trial tests a combination of an immunotherapy drug (tislelizumab) plus chemotherapy before surgery for people with a specific type of rectal cancer that has not spread to other organs. The goal is to see if this approach can shrink the tumor more effectively than standard treatment.
Nanning, GuangxiAges 18 years+ - NCT06266832RecruitingPhase 2
Short-course radiation with immunotherapy and chemo for rectal cancer
This trial tests a combination of short-course radiation, an immunotherapy drug (adebrelimab), and chemotherapy (CAPEOX) before surgery to help preserve the rectum in people with MSS/pMMR ultra-low rectal cancer. The goal is to shrink the tumor enough to avoid removing the rectum.
Hangzhou, ZhejiangAges 18 years+ - NCT06328361Recruiting
Avoiding surgery for rectal cancer after good response to treatment
This trial tests a new approach: after initial treatment (like chemo or radiation), people with rectal cancer who have a complete response may be able to avoid surgery. Instead, they are monitored closely to see if the cancer stays away.
TallinnAges 18 years+
Hear when a new Rectal Cancer, Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for rectal cancer, adenocarcinoma?
- Yes. Clin2 currently lists 251 recruiting rectal cancer, adenocarcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a rectal cancer, adenocarcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a rectal cancer, adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.